Company provided the API for Roche’s HCV drug candidate in Phase I trials.
InterMune received $10-million upon completion of a large-scale synthesis of the active pharmaceutical ingredient in Roche’s hepatitis C virus (HCV) drug candidate. ITMN-191 is currently in a Phase Ia trial.
This milestone is part of the companies’ collaboration to develop and commercialize novel protease inhibitors for the treatment of HCV.
“InterMune has successfully executed key steps in the manufacture of a sophisticated protease inhibitor molecule and transferred the materials to Roche for future studies,” says Lawrence M. Blatt, Ph.D., CSO of InterMune.